二甲双胍联合维格列汀对初治II型糖尿病患者血糖的控制效果及安全性

目的:研究二甲双胍联合维格列汀对初治Ⅱ型糖尿病患者血糖的控制效果及安全性。方法:选择2015年2月至2016年4月在我院进行治疗的2型糖尿病患者60名,按照治疗方法分为观察组和对照组,对照组使用二甲双胍治疗,观察组在对照组基础上联合维格列汀治疗,观察和比较两组治疗后的临床疗效,治疗前后血清白介素-6、肿瘤坏死因子、C反应蛋白、空腹血糖、糖化血红蛋白、餐后两小时血糖及血清淀粉酶及尿液淀粉酶水平的变化。结果:治疗后,观察组总有效率90%,明显高于对照组有效率66.7%,差异显著(P0.05)。观察组治疗后的血清白介素-6、肿瘤坏死因子、C反应蛋白、空腹血糖、糖化血红蛋白、餐后两小时血糖水平均明显低于对照组[(7.63±1.12)d vs(8.68±1.30)d、(7.23±0.95)d vs(7.89±1.20)d、(11.14±1.56)d vs(12.12±1.89)d]、[(12.12±1.89)d vs(11.20±1.34)d、(6.89±0.96)d vs(8.23±1.10)d、(1.65±0.23)d vs(3.65±0.48)d](P0.05)。治疗后,观察组的INS水平较对照组显著降低(P0.05),且GLP-1水平较对照组明显升高显著差异(P0.05)。结论:二甲双胍联合维格列汀可有效控制初治2型糖尿病患者的血糖水平,并提高治疗安全性。

Effects and Safety of Metformin Combined with Vildagliptin on the Glycemic Control for Patients with Newly Diagnosed Type 2 Diabetes Mellitus

ABSTRACT Objective: To study the effects and safety of metformin combined with vildagliptin on the glycemic control for patients with newly diagnosed type 2 diabetes mellitus. Methods: 60 patients with type 2 diabetes mellitus who were treated from February 2015 to April 2016 were selected and divided into the control group and the observation group according to different treatment methods. The control group was treated with routine treatment. The observation group was treated with vildagliptin based on the control group. The blood glucose, glycosylated hemoglobin, two-hour postprandial blood glucose and serum as well as urinal amylase were measured before and after treatment, and the clinical curative effect of the two groups and the levels of interleukin-6, tumor necrosis factor and C-reactive protein were compared. Results: After treatment, the total effective rate of observation group was 90%, which was significantly higher than that of the control group(66.7%, P<0.05). After treatment, the serum interleukin-6, tumor necrosis factor, C-reactive protein and fast- ing blood glucose, glycosylated hemoglobin and postprandial blood glucose levels were significantly lower than those of the control group[(7.63±1.12)d vs(8.68±1.30)d; (7.23±0.95)d vs(7.89±1.20)d; (11.14±1.56)d vs(12.12±1.89)d]; [(12.12±1.89)d vs(11.20±1.34)d; (6.89±0.96)d vs(8.23±1.10)d; (1.65±0.23)d vs(3.65±0.48)d] (P<0.05). After treatment, the INS level of observation group was significantly lower than that of the control group (P<0.05) and the GLP-1 level was significantly higher than that of the control group (P<0.05). Conclusion: Metformin combined with vildagliptin could effectively control the blood glucose of patients with newly diagnosed type 2 diabetes and enhance the safety.